Tirzepatide is a dual GIP and GLP-1 receptor agonist — here is what the SURPASS and SURMOUNT trials actually measured.

The short version

Tirzepatide is a once-weekly injectable medicine approved by the FDA — first for type 2 diabetes in May 2022, then for chronic weight management in November 2023, and later for obstructive sleep apnea (a condition where breathing stops during sleep). It is a synthetic 39-amino-acid peptide (a small protein) engineered to activate two hormonal receptors at once: the GIP receptor and the GLP-1 receptor. Both receptors help control blood sugar after meals, and activating both together appears to work better than activating just one.

The big numbers from clinical trials: in a 40-week head-to-head trial against another GLP-1 medicine (SURPASS-2), tirzepatide at the highest dose cut blood sugar by 2.30 percentage points versus 1.86 with the comparator ^[3]. In a 72-week obesity trial (SURMOUNT-1), participants lost an average of 20.9% of their body weight at the highest dose versus 3.1% with placebo ^[4]. Those are some of the largest effects ever measured for a medicine in these categories.

Like any potent medication, Tirzepatide comes with side effects — mostly nausea and other stomach issues, especially when starting or increasing the dose. What people report — including the downsides — is on the effects page. The full clinical record is on the research page.

What Tirzepatide is — and what makes it different

Tirzepatide (LY3298176) is the first approved dual incretin agonist — a single molecule that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. Incretin hormones are gut-derived signals released after eating; they amplify the body's insulin response and, in the case of GLP-1, also suppress glucagon (the hormone that raises blood sugar), slow gastric emptying, and reduce appetite.

Since the 1990s, selective GLP-1 receptor agonists have been developed for type 2 diabetes. Tirzepatide added a second lever: the GIP receptor. In vitro signalling assays characterized the compound as an imbalanced dual agonist — engaging the GIP receptor more completely than the GLP-1 receptor — and as biased toward cAMP generation over beta-arrestin recruitment at the GLP-1 receptor, a profile that may enhance insulin secretion ^[2]. In mice, adding the GIP arm produced greater weight reduction than a selective GLP-1 agonist ^[1]. That preclinical hypothesis played out in humans across the SURPASS and SURMOUNT programmes.

Because it is a 39-amino-acid synthetic peptide, tirzepatide carries a fatty-diacid (C20 eicosanedioic acid) modification that binds tightly to albumin in the bloodstream. That modification extends the half-life to approximately five days, enabling once-weekly subcutaneous dosing — the same convenience that selective GLP-1 receptor agonists established, but engineered into a dual-receptor molecule ^[1].

Tirzepatide peptide is administered as a subcutaneous injection. The tirzepatide injection page covers the pharmacokinetics and the clinical administration record in detail.

Glycemic efficacy in type 2 diabetes — the SURPASS record

The SURPASS programme — five large phase 3 randomised controlled trials in adults with type 2 diabetes — established tirzepatide's glycemic credentials across a range of comparators and patient populations. The headline result is SURPASS-2: a 40-week open-label head-to-head trial in 1,879 adults with type 2 diabetes comparing once-weekly tirzepatide at 5, 10, and 15 mg against semaglutide 1 mg (the only directly approved comparator head-to-head trial). Tirzepatide at 5, 10, and 15 mg reduced HbA1c (glycated haemoglobin — the standard measure of blood sugar over the prior three months) by 2.01, 2.24, and 2.30 percentage points versus 1.86 percentage points with semaglutide. All three doses were noninferior and superior to the comparator ^[3].

A network meta-analysis pooling 76 randomised trials and 15 GLP-1-based drugs in 39,246 participants in type 2 diabetes ranked tirzepatide first for both HbA1c reduction (mean difference -2.10%, 95% CI -2.47 to -1.74; SUCRA 94.2%; high confidence) and fasting plasma glucose reduction (-3.12 mmol/L; SUCRA 97.2%; high confidence) across all agents studied ^[11]. A systematic review and meta-analysis of six trials in 6,579 participants confirmed the dose-response: HbA1c declined by a weighted mean difference of 1.07 percentage points versus controls, with no increase in hypoglycemia risk as monotherapy or add-on therapy ^[9].

In Asia-Pacific adults with type 2 diabetes inadequately controlled on background oral therapy (SURPASS-AP-Combo), tirzepatide at 5, 10, and 15 mg produced HbA1c reductions of 2.24%, 2.44%, and 2.49% versus 0.95% with insulin glargine, and 75.4%, 86.0%, and 84.4% reached the HbA1c target below 7.0% ^[8]. In SURPASS J-combo in Japanese adults, mean HbA1c fell from approximately 8.5% at baseline to 6.0%, 5.6%, and 5.6% at week 52 across the three doses ^[10].

For Tirzepatide research including detailed mechanism and additional study data, see the dedicated research page.

Tirzepatide weight loss — the SURMOUNT record

The SURMOUNT programme evaluated tirzepatide in adults with obesity (BMI of 30 or higher, or 27 or higher with a weight-related condition) without type 2 diabetes. SURMOUNT-1, a 72-week double-blind randomised controlled trial in 2,539 participants, produced a mean body weight change of -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg versus -3.1% with placebo ^[4]. That 20.9% figure is among the largest weight reductions documented in a phase 3 pharmacological trial.

SURMOUNT-5, a phase 3b head-to-head trial in 751 adults with obesity but without type 2 diabetes, compared the maximum tolerated dose of tirzepatide against the maximum tolerated dose of semaglutide (the other major approved incretin agent) over 72 weeks. The mean weight change was -20.2% with tirzepatide versus -13.7% with semaglutide (P < 0.001); tirzepatide also produced greater waist circumference reductions and higher proportions of participants reaching ≥10%, 15%, 20%, and 25% weight loss thresholds ^[5].

Beyond weight and glycemic control, the trial programme has explored additional endpoints. SURMOUNT-OSA found significant reductions in apnea-hypopnea index (AHI — the number of breathing-interruption events per hour of sleep, used to grade sleep apnea severity), supporting FDA approval for moderate-to-severe obstructive sleep apnea. SUMMIT examined tirzepatide in heart failure with preserved ejection fraction (HFpEF) and obesity, and SYNERGY-NASH (now called SYNERGY-MASH) in metabolic dysfunction-associated steatohepatitis (MASH — a progressive fatty liver disease characterized by inflammation and fibrosis).

What to know before reading further

Tirzepatide is an FDA-approved prescription medicine. This site summarizes the published trial and pharmacological record; it does not provide medical advice, treatment guidance, or dosing recommendations. Every quantitative claim on this site cites the study that measured it.

The most common adverse effects in the trials — nausea, diarrhea, constipation, vomiting — are dose-related and mostly occur during dose escalation. The prescribing information carries a boxed warning (the FDA's strongest safety label) about the theoretical risk of thyroid C-cell tumors, derived from rodent data; the label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Full safety context, including what the research-use community reports anecdotally, is on Tirzepatide effects.

Negative terms in this site's scope: brand names (the two FDA-approved branded formulations are not named here — this site uses the international nonproprietary name only). Vendor terms, purchase links, and pricing comparisons are outside this site's editorial scope.